About this Journal Submit a Manuscript Table of Contents
International Journal of Breast Cancer
Volume 2012 (2012), Article ID 761917, 9 pages
http://dx.doi.org/10.1155/2012/761917
Review Article

Target Points in Trastuzumab Resistance

National Institute of Genetic Engineering and Biotechnology (NIGEB), Pajoohesh Boulevard, Tehran-Karaj HWY, Km 15, Tehran 1497716316, Iran

Received 31 October 2011; Accepted 11 November 2011

Academic Editor: Rita Nahta

Copyright © 2012 Sahar Shojaei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National Cancer Institute, “SEER Cancer Statistics Review, 1975–2005,” http://seer.cancer.gov/csr/1975_2005/.
  2. A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2008,” Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. H. W. Lo, S. C. Wang, and M.C. Hung, “Novel signaling pathways in breast cancer,” in Breast Cancer and Molecular Medicine, pp. 823–839, 2006. View at Publisher · View at Google Scholar
  4. I. Rubin and Y. Yarden, “The basic biology of HER2,” Annals of Oncology, vol. 12, supplement 1, pp. S3–S8, 2001. View at Scopus
  5. J. C. Chang, “HER2 inhibition: from discovery to clinical practice,” Clinical Cancer Research, vol. 13, no. 1, pp. 1–3, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. J. S. Ross, J. A. Fletcher, G. P. Linette et al., “The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy,” Oncologist, vol. 8, no. 4, pp. 307–325, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. M. D. Pegram, A. Lipton, D. F. Hayes, et al., “Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment,” Journal of Clinical Oncology, vol. 16, no. 8, pp. 2659–2671, 1998.
  8. M. F. Press, D. J. Slamon, K. J. Flom, J. Park, J. Y. Zhou, and L. Bernstein, “Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens,” Journal of Clinical Oncology, vol. 20, no. 14, pp. 3095–3105, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. H. B. Muss, A. D. Thor, D. A. Berry et al., “c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer,” The New England Journal of Medicine, vol. 330, no. 18, pp. 1260–1266, 1994. View at Publisher · View at Google Scholar · View at PubMed
  10. A. D. Thor, D. A. Berry, D. R. Budman et al., “erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer,” Journal of the National Cancer Institute, vol. 90, no. 18, pp. 1346–1360, 1998. View at Scopus
  11. D. J. Slamon, G. M. Clark, and S. G. Wong, “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987. View at Scopus
  12. D. J. Slamon, W. Godolphin, L. A. Jones et al., “Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer,” Science, vol. 244, no. 4905, pp. 707–712, 1989. View at Scopus
  13. G. A. Niehans, T. P. Singleton, D. Dykoski, and D. T. Kiang, “Stability of HER-2/neu expression over time and at multiple metastatic sites,” Journal of the National Cancer Institute, vol. 85, no. 15, pp. 1230–1235, 1993. View at Scopus
  14. A. Choudhury and R. Kiessling, “Her-2/neu as a paradigm of a tumor-specific target for therapy,” Breast Disease, vol. 20, pp. 25–31, 2004. View at Scopus
  15. P. J. Barnes, R. Boutilier, D. Chiasson, and D. Rayson, “Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression,” Breast Cancer Research and Treatment, vol. 91, no. 2, pp. 173–178, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. T. Fehm, P. Maimonis, A. Katalinic, and W. H. Jäger, “The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer,” Oncology, vol. 55, no. 1, pp. 33–38, 1998. View at Scopus
  17. J. Baselga, L. Norton, J. Albanell, Y. M. Kim, and J. Mendelsohn, “Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts,” Cancer Research, vol. 58, no. 13, pp. 2825–2831, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Ginestier, M. H. Hur, E. Charafe-Jauffret et al., “ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome,” Cell Stem Cell, vol. 1, no. 5, pp. 555–567, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. H. Korkaya, A. Paulson, F. Iovino, and M. S. Wicha, “HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion,” Oncogene, vol. 27, no. 47, pp. 6120–6130, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. G. Dontu, M. Al-Hajj, W. M. Abdallah, M. F. Clarke, and M. S. Wicha, “Stem cells in normal breast development and breast cancer,” Cell Proliferation, vol. 36, supplement 1, pp. 59–72, 2003. View at Publisher · View at Google Scholar
  21. M. Razandi, A. Pedram, S. T. Park, and E. R. Levin, “Proximal events in signaling by plasma membrane estrogen receptors,” Journal of Biological Chemistry, vol. 278, no. 4, pp. 2701–2712, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. B. S. Hendriks, G. Orr, A. Wells, H. S. Wiley, and D. A. Lauffenburger, “Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells,” Journal of Biological Chemistry, vol. 280, no. 7, pp. 6157–6169, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. J. Shou, S. Massarweh, C. K. Osborne et al., “Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer,” Journal of the National Cancer Institute, vol. 96, no. 12, pp. 926–935, 2004. View at Scopus
  24. P. Carter, L. Presta, C. M. Gorman et al., “Humanization of an anti-p185(HER2) antibody for human cancer therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 10, pp. 4285–4289, 1992. View at Publisher · View at Google Scholar · View at Scopus
  25. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Ghosh, A. Narasanna, S. E. Wang et al., “Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers,” Cancer Research, vol. 71, no. 5, pp. 1871–1882, 2011. View at Publisher · View at Google Scholar · View at PubMed
  27. R. Nahta and F. J. Esteva, “Herceptin: mechanisms of action and resistance,” Cancer Letters, vol. 232, no. 2, pp. 123–138, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. R. Nahta, T. Takahashi, N. T. Ueno, M. C. Hung, and F. J. Esteva, “P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells,” Cancer Research, vol. 64, no. 11, pp. 3981–3986, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. R. Gennari, S. Menard, F. Fagnoni et al., “Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2,” Clinical Cancer Research, vol. 10, no. 17, pp. 5650–5655, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. C. L. Vogel, M. A. Cobleigh, D. Tripathy et al., “Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 719–726, 2002. View at Publisher · View at Google Scholar
  31. A. D. Seidman, D. Berry, C. Cirrincione et al., “Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1642–1649, 2008. View at Publisher · View at Google Scholar · View at PubMed
  32. M. A. Molina, J. Codony-Servat, J. Albanell, F. Rojo, J. Arribas, and J. Baselga, “Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells,” Cancer Research, vol. 61, no. 12, pp. 4744–4749, 2001.
  33. M. N. Fornier, A. D. Seidman, M. K. Schwartz et al., “Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate,” Annals of Oncology, vol. 16, no. 2, pp. 234–239, 2005. View at Publisher · View at Google Scholar · View at PubMed
  34. M. Cuello, S. A. Ettenberg, A. S. Clark et al., “Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2,” Cancer Research, vol. 61, no. 12, pp. 4892–4900, 2001.
  35. T. Ben-Kasus, B. Schechter, S. Lavi, Y. Yarden, and M. Sela, “Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 9, pp. 3294–3299, 2009. View at Publisher · View at Google Scholar · View at PubMed
  36. L. Arnould, M. Gelly, F. Penault-Llorca et al., “Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?” British Journal of Cancer, vol. 94, no. 2, pp. 259–267, 2006. View at Publisher · View at Google Scholar · View at PubMed
  37. Y. Nagata, K. H. Lan, X. Zhou et al., “PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients,” Cancer Cell, vol. 6, no. 2, pp. 117–127, 2004. View at Publisher · View at Google Scholar · View at PubMed
  38. K. Berns, H. M. Horlings, B. T. Hennessy et al., “A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer,” Cancer Cell, vol. 12, no. 4, pp. 395–402, 2007. View at Publisher · View at Google Scholar · View at PubMed
  39. M. Scaltriti, F. Rojo, A. Ocaña et al., “Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer,” Journal of the National Cancer Institute, vol. 99, no. 8, pp. 628–638, 2007. View at Publisher · View at Google Scholar · View at PubMed
  40. F. M. Yakes, W. Chinratanalab, C. A. Ritter, W. King, S. Seelig, and C. L. Arteaga, “Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action,” Cancer Research, vol. 62, no. 14, pp. 4132–4141, 2002.
  41. L. H. Saal, K. Holm, M. Maurer, et al., “PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma,” Cancer Research, vol. 65, no. 7, pp. 2554–2559, 2005. View at Publisher · View at Google Scholar · View at PubMed
  42. R. M. Neve, H. Sutterlüty, N. Pullen et al., “Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells,” Oncogene, vol. 19, no. 13, pp. 1647–1656, 2000.
  43. H. C. Workman, C. Sweeney, and K. L. Carraway III, “The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms,” Cancer Research, vol. 69, no. 7, pp. 2845–2852, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. S. A. Price-Schiavi, S. Jepson, P. Li et al., “Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance,” International Journal of Cancer, vol. 99, no. 6, pp. 783–791, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. B. Stockmeyer, T. Beyer, W. Neuhuber et al., “Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells,” Journal of Immunology, vol. 171, no. 10, pp. 5124–5129, 2003. View at Scopus
  46. D. Graus-Porta, R. R. Beerli, J. M. Daly, and N. E. Hynes, “ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling,” EMBO Journal, vol. 16, no. 7, pp. 1647–1655, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. S. Diermeier, G. Horváth, R. Knuechel-Clarke, F. Hofstaedter, J. Szöllosi, and G. Brockhoff, “Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation,” Experimental Cell Research, vol. 304, no. 2, pp. 604–619, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. A. B. Motoyama, N. E. Hynes, and H. A. Lane, “The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides,” Cancer Research, vol. 62, no. 11, pp. 3151–3158, 2002. View at Scopus
  49. K. L. Blackwell, H. J. Burstein, A. M. Storniolo et al., “Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1124–1130, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. D. B. Agus, C. J. Sweeney, M. J. Morris et al., “Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy,” Journal of Clinical Oncology, vol. 25, no. 6, pp. 675–681, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. H. Sariola and M. Saarma, “Novel functions and signalling pathways for GDNF,” Journal of Cell Science, vol. 116, no. 19, pp. 3855–3862, 2003. View at Publisher · View at Google Scholar · View at PubMed
  52. J. L. Guan, “Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer,” IUBMB Life, vol. 62, no. 4, pp. 268–276, 2010. View at Publisher · View at Google Scholar · View at PubMed
  53. A. Gentile, L. Trusolino, and P. M. Comoglio, “The Met tyrosine kinase receptor in development and cancer,” Cancer and Metastasis Reviews, vol. 27, no. 1, pp. 85–94, 2008. View at Publisher · View at Google Scholar · View at PubMed
  54. S. Esseghir, S. K. Todd, T. Hunt et al., “A role for glial cell-derived neurotrophic factor-induced expression by inflammatory cytokines and RET/GFRα1 receptor up-regulation in breast cancer,” Cancer Research, vol. 67, no. 24, pp. 11732–11741, 2007. View at Publisher · View at Google Scholar · View at PubMed
  55. N. B. Berry, M. Fan, and K. P. Nephew, “Estrogen receptor-α hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome,” Molecular Endocrinology, vol. 22, no. 7, pp. 1535–1551, 2008. View at Publisher · View at Google Scholar · View at PubMed
  56. I. Plaza-Menacho, A. Morandi, D. Robertson et al., “Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance,” Oncogene, vol. 29, no. 33, pp. 4648–4657, 2010. View at Publisher · View at Google Scholar · View at PubMed
  57. M. A. Molina, R. Sáez, E. E. Ramsey et al., “NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer,” Clinical Cancer Research, vol. 8, no. 2, pp. 347–353, 2002.
  58. S. I. Helle, “The insulin-like growth factor system in advanced breast cancer,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 18, no. 1, pp. 67–79, 2004. View at Publisher · View at Google Scholar
  59. Y. Lu, X. Zi, Y. Zhao, D. Mascarenhas, and M. Pollak, “Insulin-like growth factor-I receptor signaling and resistance to transtuzumab (Herceptin),” Journal of the National Cancer Institute, vol. 93, no. 24, pp. 1852–1857, 2001.
  60. M. Hidalgo and E. K. Rowinsky, “The rapamycin-sensitive signal transduction pathway as a target for cancer therapy,” Oncogene, vol. 19, no. 56, pp. 6680–6686, 2000. View at Publisher · View at Google Scholar · View at PubMed
  61. R. Nahta, D. Yu, M. C. Hung, G. N. Hortobagyi, and F. J. Esteva, “Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer,” Nature Clinical Practice Oncology, vol. 3, no. 5, pp. 269–280, 2006. View at Publisher · View at Google Scholar · View at PubMed
  62. R. Nahta, L. X. H. Yuan, B. Zhang, R. Kobayashi, and F. J. Esteva, “Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells,” Cancer Research, vol. 65, no. 23, pp. 11118–11128, 2005. View at Publisher · View at Google Scholar · View at PubMed
  63. P. P. Pandolfi, “Breast cancer—loss of PTEN predicts resistance to treatment,” The New England Journal of Medicine, vol. 351, no. 22, pp. 2337–2338, 2004. View at Publisher · View at Google Scholar · View at PubMed
  64. B. Dave, I. Migliaccio, M. C. Gutierrez et al., “Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2—overexpressing locally advanced breast cancers,” Journal of Clinical Oncology, vol. 29, no. 2, pp. 166–173, 2011. View at Publisher · View at Google Scholar · View at PubMed
  65. X. F. Le, F. Pruefer, and R. C. Bast, “HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways,” Cell Cycle, vol. 4, no. 1, pp. 87–95, 2005.
  66. H. A. Lane, A. B. Motoyama, I. Beuvink, and N. E. Hynes, “Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling,” Annals of Oncology, vol. 12, no. 1, pp. S21–S22, 2001.
  67. M. Scaltriti, P. J. Eichhorn, J. Cortés et al., “Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 9, pp. 3761–3766, 2011. View at Publisher · View at Google Scholar · View at PubMed
  68. Y. Kataoka, T. Mukohara, H. Shimada, N. Saijo, M. Hirai, and H. Minami, “Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines,” Annals of Oncology, vol. 21, no. 2, pp. 255–262, 2010. View at Publisher · View at Google Scholar · View at PubMed
  69. K. Keyomarsi, S. L. Tucker, T. A. Buchholz et al., “Cyclin E and survival in patients with breast cancer,” The New England Journal of Medicine, vol. 347, no. 20, pp. 1566–1575, 2002. View at Publisher · View at Google Scholar · View at PubMed
  70. E. A. Mittendorf, Y. Liu, S. L. Tucker et al., “A novel interaction between HER2/neu and cyclin E in breast cancer,” Oncogene, vol. 29, no. 27, pp. 3896–3907, 2010. View at Publisher · View at Google Scholar · View at PubMed
  71. S. Cooley, L. J. Burns, T. Repka, and J. S. Miller, “Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu,” Experimental Hematology, vol. 27, no. 10, pp. 1533–1541, 1999. View at Publisher · View at Google Scholar · View at Scopus
  72. R. A. Clynes, T. L. Towers, L. G. Presta, and J. V. Ravetch, “Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets,” Nature Medicine, vol. 6, no. 4, pp. 443–446, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. T. J. Yeatman, “A renaissance for SRC,” Nature Reviews Cancer, vol. 4, no. 6, pp. 470–480, 2004. View at Scopus
  74. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at Scopus
  75. J. T. Parsons and S. J. Parsons, “Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways,” Current Opinion in Cell Biology, vol. 9, no. 2, pp. 187–192, 1997. View at Publisher · View at Google Scholar · View at Scopus
  76. M. A. Rivas, M. Tkach, W. Beguelin et al., “Transactivation of ErbB-2 induced by tumor necrosis factor α promotes NF-κB activation and breast cancer cell proliferation,” Breast Cancer Research and Treatment, vol. 122, no. 1, pp. 111–124, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. J. E. Damen, L. Liu, R. L. Cutler, and G. Krystal, “Erythropoietin stimulates the tyrosine phosphorylation of Shc and its association with Grb2 and a 145-Kd tyrosine phosphorylated protein,” Blood, vol. 82, no. 8, pp. 2296–2303, 1993. View at Scopus
  78. K. Liang, F. J. Esteva, C. Albarracin et al., “Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation,” Cancer Cell, vol. 18, no. 5, pp. 423–435, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. S. Zhang, W. C. Huang, P. Li et al., “Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways,” Nature Medicine, vol. 17, no. 4, pp. 461–469, 2011. View at Publisher · View at Google Scholar · View at PubMed
  80. F. Andre, M. Campone, R. O'Regan et al., “Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab,” Journal of Clinical Oncology, vol. 28, no. 34, pp. 5110–5115, 2010. View at Publisher · View at Google Scholar · View at PubMed
  81. D. A. Tice, J. S. Biscardi, A. L. Nickles, and S. J. Parsons, “Mechanism of biological synergy between cellular Src and epidermal growth factor receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 4, pp. 1415–1420, 1999. View at Publisher · View at Google Scholar · View at Scopus